SCHEMBL4835923

SCHEMBL4835923

CNCc1cc(F)nc(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.33
CYP3A4 P08684 2/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PRMT6 Q96LA8 3/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A3 Q01959 2/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
NCF1 P14598 1/20 0.31
LOXL2 Q9Y4K0 1/20 0.31
HTR2A P28223 2/20 0.30
KCNH2 Q12809 1/20 0.30
HTR1A P08908 1/20 0.30
HTR1D P28221 1/20 0.30
HTR1B P28222 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4832258 0.86 KDM4E (0.39) KDM4ECYP3A4MAPTSMN1; SMN2PRMT6
SCHEMBL4826584 0.86 KDM4E (0.39) KDM4ECYP3A4MAPTPRMT6SLC6A2
SCHEMBL14614692 0.77 NOS1 (0.40)
SCHEMBL4837374 0.69 KDM4E (0.37) KDM4ESLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL4826754 0.69 KDM4E (0.40) KDM4ESLC6A2SLC6A4HTR2AKCNH2
SCHEMBL13339967 0.68 KDM4E (0.52) KDM4ECYP3A4MAPTPRMT6SLC6A2
SCHEMBL4826459 0.68 METAP2 (0.43) KDM4ECYP3A4MAPTSLC6A4HTR2A
SCHEMBL3350251 0.68 KDM4E (0.42) KDM4ECYP3A4MAPTPRMT6SLC6A4
SCHEMBL3340427 0.68 CD274 (0.46) KDM4ECYP3A4MAPTSLC6A2SLC6A4
SCHEMBL12536053 0.67 LOXL2 (0.57) KDM4ECYP3A4MAPTPRMT6LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442692-B2 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2008-10-28 US disclosed
EP-1707564-B1 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-09-12 EP disclosed
US-20060223830-A1 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2006-10-05 US disclosed
WO-2006103342-A2 INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2006-10-05 WO disclosed
EP-1707564-A2 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2006-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223830-A1 Indanyl-piperazine compounds HTR4, NR4A1, NR4A3 KDM4E 1559/4885CYP3A4 40/4885MAPT 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.